Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in BRAF, NRAS, or NF1 form 10% of human melanomas and are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanom...

Descripción completa

Detalles Bibliográficos
Autores principales: Krebs, Fanny Seraphine, Moura, Bianca, Missiaglia, Edoardo, Aedo-Lopez, Veronica, Michielin, Olivier, Tsantoulis, Petros, Bisig, Bettina, Trimech, Mounir, Zoete, Vincent, Homicsko, Krisztian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003177/
https://www.ncbi.nlm.nih.gov/pubmed/36901951
http://dx.doi.org/10.3390/ijms24054520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003177/
https://www.ncbi.nlm.nih.gov/pubmed/36901951
http://dx.doi.org/10.3390/ijms24054520

Ejemplares similares